Benefits
Immune improvement RCT (PMC9410671 LDH cytotoxicity)
PMC9410671 — CONSORT-randomized double-blinded placebo-controlled trial of Phellinus linteus extract for IMMUNITY IMPROVEMENT. Lactate dehydrogenase (LDH) cytotoxicity assay primary endpoint. Foundational human clinical evidence — first registered RCT for PL immune enhancement (Korean regulatory pathway).
Sanghuang 8-week immune RCT 98-pt (PMC8627044)
PMC8627044 (doi:10.1186/s13063-021-05740-5) — randomized double-blind placebo-controlled trial. 98 participants randomized to PL mycelium extract (KCTC0399BP strain, 1000 mg/day) vs placebo for 8 weeks. Endpoints: NK cell activity, TNF-α, IFN-γ, IL-1β/2/6/12, IgG1/IgG2/IgM. Daejeon University Korean Medicine Hospital — multi-cytokine immune assessment.
Pancreatic cancer adjunct (case report)
Memorial Sloan Kettering: ONE study suggests P. linteus may be helpful as ADD-ON treatment in some PANCREATIC CANCER patients. Few case reports of regression in liver + prostate cancers. HONEST: well-designed trials NEEDED to confirm. Important integrative oncology context — preliminary signal only.
Antitumor immunomodulatory mechanism (PMC3445909)
PMC3445909 — review of P. linteus antitumor activity. Polysaccharides, peptide/protein complexes + low MW compounds (hispolon, caffeic acid, davallialactone, interfungins A, inoscavin A). Mechanism: increased macrophage cytokine production + B-cell activation + NK cell cytotoxicity. Modulates cell proliferation, apoptosis, angiogenesis, invasive behavior, chemoprevention genes.
MeshimaMax combination preclinical (PMC7469031)
PMC7469031 — MeshimaMax (P. linteus + Sasa senanensis bamboo + Chaga) preclinical combination. Significantly INHIBITED tumor growth in S180 mouse sarcoma. AOM/DSS colon cancer + DMBA breast cancer suppressed. ENHANCED effect when combined with anticancer chemotherapy. Macrophage phagocytosis activation. PRECLINICAL mouse evidence.
HONEST autoimmune skin warning (pemphigus)
HONEST safety warning: P. linteus use resulted in WORSENING of autoimmune skin condition PEMPHIGUS (blisters, itching, burning) per case report. Mechanism: immune activation may exacerbate autoimmune conditions. Important contraindication for autoimmune disease populations. Caution in autoimmune contexts.
Mulberry tree parasitic origin (TCM heritage)
P. linteus is yellow/orange perennial mushroom selectively parasitic on MULBERRY TREES (Morus). Hymenochaetaceae basidiomycete with 220 known Phellinus species mainly tropical. Used in traditional Oriental medicine in Japan ('meshimakobu'), China ('sanghuang'), Korea for >40 years. First Japanese study (1960s) demonstrated strongest antitumor effects vs other mushrooms.
Mechanism of action
Polysaccharide immune cell activation
Polysaccharide fractions increase macrophage + B-cell cytokine production + NK cell cytotoxic activity. Mechanism: pattern recognition receptor activation supporting innate + adaptive immunity.
Hispolon + bioactive small molecules
Low MW compounds: hispolon, caffeic acid, davallialactone, interfungins A, inoscavin A. Mechanism: multi-compound bioactivity with anti-tumor + anti-inflammatory + anti-oxidant effects.
Cell proliferation + apoptosis modulation
Modulates expression/activity of genes involved in cell proliferation, apoptosis, angiogenesis, invasive behavior, chemoprevention. Mechanism: multi-target gene regulation in cancer biology.
Macrophage phagocytosis activation
MeshimaMax combination activates macrophage phagocytosis (RAW264.7 cells, living yeast cells, synthetic nanoparticles). Mechanism: innate immunity enhancement supporting cancer prevention.
Cancer cell selectivity (preclinical)
Cytotoxicity assay: IC50 >1 mg/mL. Normal cells 2-3× more tolerant than cancer cells. Mechanism: selective cancer cell vulnerability supporting therapeutic window. Preclinical mouse evidence only.
Th1/Th2 immune balance modulation
Modulates Th1/Th2 immune balance + amelioration of inflammation through innate immunity activation. Mechanism: immunomodulation distinguishing context-dependent effects.
Clinical trials
CONSORT-randomized double-blinded placebo-controlled trial.
Healthy participants. Phellinus linteus extract vs placebo. LDH cytotoxicity assay primary endpoint (Korean regulatory pathway requirement for functional supplement approval).
First registered RCT for PL immune enhancement (Korean regulatory pathway). Foundational human clinical evidence demonstrating immunity improvement. Important regulatory milestone — supports use of PL as raw material in functional supplements + medicines in Korea.
Randomized double-blind placebo-controlled trial (Ku YH, Lee H, Ryu HY, Kang JH 2021, doi:10.1186/s13063-021-05740-5). Daejeon University College of Korean Medicine + Cheonan Korean Medicine Hospital.
98 participants randomly divided into experimental group (PL mycelium extract from KCTC0399BP strain, 1000 mg) vs control (placebo). 8-week intervention. Blood tests at baseline + 8 weeks.
Endpoints: NK cell activity, TNF-α, IFN-γ, IL-1β, IL-2, IL-6, IL-12, IgG1, IgG2, IgM. Multi-cytokine immune assessment with strain-specific PL mycelium extract. Foundational strain-specific clinical evidence based on pilot study results.
Review article (PMC3445909).
Synthesis of P. linteus antitumor research — in vitro + in vivo + preclinical + 3 case reports.
Polysaccharides + peptide/protein complexes + low MW compounds (hispolon, caffeic acid, davallialactone, interfungins A, inoscavin A) — increase macrophage cytokine production + B-cell activation + NK cell cytotoxicity. Modulates gene expression in cell proliferation, apoptosis, angiogenesis, invasive behavior, chemoprevention. 3 case reports of tumor regression with PL extract use suggest CAM potential — well-designed trials needed.
About this ingredient
PHELLINUS LINTEUS (Berk. et Curt.) Aoshima is a YELLOW/ORANGE PERENNIAL FUNGUS selectively PARASITIC on MULBERRY TREES (Morus). HYMENOCHAETACEAE BASIDIOMYCETE — 220 known Phellinus species mainly tropical. JAPANESE name 'MESHIMAKOBU', KOREAN name 'SANGHUANG'. Used in TRADITIONAL ORIENTAL MEDICINE in Japan + China + Korea for >40 years. Original 1960s Japanese study demonstrated PL has STRONGEST ANTITUMOR EFFECTS compared to other mushrooms. Active compounds: POLYSACCHARIDES, PROTEOGLYCANS, HISPOLON, CAFFEIC ACID, DAVALLIALACTONE, INTERFUNGINS A, INOSCAVIN A. PIVOTAL CLINICAL EVIDENCE: PMC9410671 — CONSORT-randomized double-blinded placebo-controlled trial of PL extract for IMMUNITY IMPROVEMENT. Lactate dehydrogenase (LDH) cytotoxicity assay primary endpoint (Korean regulatory pathway requirement for functional supplements + medicines). FIRST registered RCT for PL immune enhancement. PMC8627044 (Ku YH, Lee H, Ryu HY, Kang JH 2021, doi:10.1186/s13063-021-05740-5) — randomized double-blind placebo-controlled trial. 98 participants randomized to PL mycelium extract (KCTC0399BP strain, 1000 mg/day) vs placebo for 8 weeks. Endpoints: NK cell activity, TNF-α, IFN-γ, IL-1β/2/6/12, IgG1/IgG2/IgM. Daejeon University College of Korean Medicine + Cheonan Korean Medicine Hospital. PMC3445909 antitumor mechanism review. PMC7469031 MeshimaMax (PL + Sasa senanensis bamboo + Chaga) preclinical combination — S180 mouse sarcoma + AOM/DSS colon cancer + DMBA breast cancer + chemotherapy enhancement. Memorial Sloan Kettering Cancer Center — ONE study suggests PL may be helpful as ADD-ON in some PANCREATIC CANCER patients. Few case reports of regression in liver + prostate cancers. HONEST: well-designed trials NEEDED to confirm.
MECHANISMS: POLYSACCHARIDE IMMUNE CELL activation (macrophage cytokine + B-cell + NK cell cytotoxicity); HISPOLON + bioactive small molecules; CELL PROLIFERATION + APOPTOSIS modulation (cancer biology gene regulation); MACROPHAGE PHAGOCYTOSIS activation (RAW264.7 cells, yeast cells, synthetic nanoparticles); CANCER CELL SELECTIVITY (IC50 >1 mg/mL, normal cells 2-3× tolerant); Th1/Th2 IMMUNE BALANCE modulation. EVIDENCE: 3/5 reflects: (1) PMC9410671 CONSORT-RCT for PL immunity (Korean regulatory pathway), (2) PMC8627044 98-pt 8-week double-blind RCT (KCTC0399BP strain, multi-cytokine endpoints), (3) PMC3445909 antitumor mechanism comprehensive review, (4) PMC7469031 MeshimaMax preclinical combination evidence, (5) Memorial Sloan Kettering pancreatic cancer adjunct case report, (6) >40 years traditional Oriental medicine use record (Japan/Korea/China), (7) 1960s Japanese study foundational antitumor evidence, (8) HONEST CRITICAL CAVEAT — pemphigus worsening case report (autoimmune contraindication), (9) HONEST limitation — clinical RCTs limited; mostly preclinical + traditional use, (10) higher-evidence than typical 'sanghuang' supplement due to dedicated Korean regulatory pathway research. SAFETY: Generally well-tolerated in clinical trials BUT pemphigus worsening case warrants autoimmune caution. Best positioned as: (a) IMMUNE FUNCTION SUPPORT (PMC9410671 + PMC8627044 evidence), (b) INTEGRATIVE ONCOLOGY ADJUNCT for pancreatic cancer (preliminary evidence + specialist guidance required), (c) NK CELL ACTIVITY enhancement (PMC8627044 endpoint focus), (d) CYTOKINE MODULATION (multi-cytokine immune balance), (e) KCTC0399BP STRAIN-SPECIFIC mycelium extract (PMC8627044 evidence-matched formulation), (f) AUTOIMMUNE CONDITIONS: SIGNIFICANT CAUTION (pemphigus worsening case), (g) IMMUNOCOMPROMISED: caution (immune activation potential), (h) PREGNANCY: limited specific data, (i) CANCER PATIENTS: discuss with oncologist before integrative use, (j) higher-evidence than typical immune mushroom due to Korean regulatory pathway clinical research. Honest framing: Phellinus linteus has SOLID EMERGING EVIDENCE for immune support — PMC9410671 CONSORT-RCT + PMC8627044 98-pt 8-week double-blind RCT (KCTC0399BP strain) + PMC3445909 antitumor mechanism review establish clinical + mechanism foundation. >40 year Japanese antitumor research history + 1960s landmark study supports cultural validity.
CRITICAL HONEST LIMITATIONS: per Memorial Sloan Kettering — data in humans VERY LIMITED; only ONE pancreatic cancer adjunct study + few case reports of liver/prostate regression. WELL-DESIGNED TRIALS NEEDED. PEMPHIGUS WORSENING case report is significant autoimmune contraindication — immune activation may exacerbate autoimmune conditions. KCTC0399BP strain (PMC8627044) supports trial-matched formulation. MeshimaMax combination preclinical evidence (PL + bamboo + Chaga) supports synergy framework. Mulberry tree parasitic origin distinguishes from other medicinal mushrooms. Reasonable immune support adjunct + integrative oncology context based on emerging Korean regulatory pathway evidence — particularly compelling for those wanting NK cell + cytokine modulation.
CAUTION: avoid in autoimmune conditions due to pemphigus case + immune activation mechanism.